MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8000
-0.0100
-1.23%
After Hours: 0.8300 +0.03 +3.75% 17:09 10/18 EDT
OPEN
0.8200
PREV CLOSE
0.8100
HIGH
0.8500
LOW
0.7800
VOLUME
535.84K
TURNOVER
--
52 WEEK HIGH
5.44
52 WEEK LOW
0.7800
MARKET CAP
37.00M
P/E (TTM)
-0.3455
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLCM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BLCM News

  • Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire.09/30 20:07
  • Top Ranked Momentum Stocks to Buy for September 23rd
  • Zacks.09/23 15:54
  • 22 Healthcare Stocks Moving In Monday's Pre-Market Session
  • Benzinga.09/16 12:29
  • Bellicum: Moving Toward MAA Submission For Rivo-Cel
  • Seeking Alpha - Article.09/09 15:36

More

Industry

Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.94%

Hot Stocks

Name
Price
%Change

About BLCM

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More

Webull offers Bellicum Pharmaceuticals Inc (BLCM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.